Perspective Therapeutics CATX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$103.12M-30.1% | -$79.28M-70.5% | -$46.51M-521% | -$7.49M-32.5% | ||
| $3.25M+41.0% | $2.31M+134% | $986K— | —— | ||
| $8.97M+66.4% | $5.39M+44.1% | $3.74M— | —— | ||
| $0— | —— | $0— | —— | ||
| -$110K— | —— | -$198K+51.1% | -$405K— | ||
| —— | —— | -$359K-113% | $2.67M— | ||
| —— | —— | $1.57M— | —— | ||
| $2.01M-44.1% | $3.6M— | —— | —— | ||
| -$634K-132% | $1.97M+507% | $325K+64.1% | $198K— | ||
| $331K+502% | $55K— | —— | $26K— | ||
| —— | —— | -$410K— | —— | ||
| —— | —— | $0— | —— | ||
| —— | $880K— | $0— | —— | ||
| -$82.48M-351% | -$18.29M+50.4% | -$36.91M-255% | -$10.4M— | ||
| $12.75M-76.6% | $54.41M+4,976% | $1.07M— | —— | ||
| $119.84M-27.3% | $164.78M— | $0— | —— | ||
| $0-100% | $78.73M— | —— | $12.54M— | ||
| $0— | —— | $0— | —— | ||
| $41.23M+119% | -$218.93M— | —— | —— | ||
| $52K+8.3% | $48K-29.4% | $68K— | $0— | ||
| $371K-99.9% | $275.81M— | —— | $0— | ||
| $10.32M-96.4% | $289.39M+36,764% | $785K+1,302% | $56K— | ||
| —— | —— | -$11.76M— | —— | ||
| —— | $0— | —— | —— | ||
| —— | $880K— | $0— | —— | ||
| —— | —— | $0— | —— | ||
| $2.01M-44.1% | $3.6M— | —— | —— | ||
| $331K+502% | $55K— | $0— | —— | ||
| -$634K-132% | $1.97M+507% | $325K+64.1% | $198K— | ||
| —— | —— | -$410K— | —— | ||
| $135K+87.5% | $72K+300% | $18K— | —— | ||
| $173.95M— | $0— | —— | —— | ||
| $52K+8.3% | $48K-29.4% | $68K— | $0— | ||
| —— | —— | —— | —— | ||
| $205K-90.3% | $2.12M+161% | $811K— | —— | ||
| -$95.23M-31.0% | -$72.71M-91.4% | -$37.99M— | —— | ||
| -$95.23M-31.0% | -$72.71M-91.4% | -$37.99M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Perspective Therapeutics generate?
- Perspective Therapeutics (CATX) generated -$92.4M in operating cash flow over the trailing twelve months.
- What is Perspective Therapeutics's free cash flow?
- After $15.0M of capital expenditures, Perspective Therapeutics's free cash flow was -$107.3M over the trailing twelve months, down 3.5% year over year.
- Where does Perspective Therapeutics's cash flow data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
